{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:38:32Z","timestamp":1789501112416,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of computed tomography (CT)-guided co-ablation in patients with hepatic metastases from malignant melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Clinical data of 79 patients with hepatic metastases from malignant melanoma who underwent co-ablation (integration of cryoablation and thermal ablation) and programmed death 1 (PD-1) treatment between October 2019 and January 2024 were retrospectively analyzed. The patients were divided into group A (n = 50), patients who received co-ablation, and group B (n = 29), patients who received PD-1 treatment. In group A, treatment efficacy and safety, changes in lymphocyte subsets, Th1\/Th2 cell cytokines before and 3 weeks after treatment, and adverse events (AEs) during co-ablation were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Co-ablation exhibited favorable clinical efficacy in the treatment of hepatic metastases from malignant melanoma. The rates of complete remission (CR), partial remission (PR), progressive disease (PD), stable disease (SD), and disease control rate (DCR) were 56.0%, 24.0%, 8.0%, 12.0%, and 92.0%, respectively. In group B, the CR, PR, PD, SD, and DCR rates were 10.3%, 24.1%, 31.0%, 34.5%, and 68.9%, respectively. Three weeks after treatment, the levels of Th2-related cytokine interleukin-10, CD3\u2013CD16 + CD56+, and CD8 + CD25 + significantly decreased compared with baseline, with group A demonstrating lower levels than group B. At the end of the follow-up, 16 patients (32%) in group A and 16 (55.2%) in group B had died. The median progression-free survival was 20.2 months in group A, which was significantly longer than the 7.93 months in group B (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.005). The median overall survival in group A was 20.2 months, which was significantly longer than the 13.5 months in group B (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.025). The intraoperative AEs during co-ablation included mild pain (4.0%), hepatic arterial bleeding (2.0%), minor subcapsular bleeding (4.0%), minor pneumothorax (4.0%), and vomiting (2.0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The CT-guided co-ablation system exhibited favorable clinical efficacy and was associated with a low incidence of AEs in the treatment of hepatic metastases from malignant melanoma, indicating its potential clinical value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2146_24","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:06:48Z","timestamp":1756998408000},"page":"892-899","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of the CT-guided co-ablation system in the treatment of malignant melanoma with hepatic metastasis"],"prefix":"10.4103","volume":"21","author":[{"given":"Xueyan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Therapy, Sun Yat-sen University Cancer Center, Guangzhou Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulijiayina","family":"Nuerhashi","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Therapy, Sun Yat-sen University Cancer Center, Guangzhou Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujun","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Therapy, Sun Yat-sen University Cancer Center, Guangzhou Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Therapy, Sun Yat-sen University Cancer Center, Guangzhou Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"R1-20250905","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00262-020-02566-z","article-title":"Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: An ambispective, proof-of-concept cohort study","volume":"69","author":"Shen","year":"2020","journal-title":"Cancer lmmunol lmmun"},{"key":"R2-20250905","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"R3-20250905","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/1759-7714.13779","article-title":"Co-ablation versus cryoablation for the treatment of stage III-IV non-small cell lung cancer: A prospective, noninferiority, randomized, controlled trial (RCT)","volume":"12","author":"Yang","year":"2021","journal-title":"Thorac Cancer"},{"key":"R4-20250905","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/hep.27548","article-title":"Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma","volume":"61","author":"Wang","year":"2015","journal-title":"Hepatology"},{"key":"R5-20250905","first-page":"705","article-title":"Expert consensus on clinical practice of percutaneous multi-modal cold and hot ablation for treatment of pulmonary malignant tumor","volume":"17","author":"Gao","year":"2020","journal-title":"Chinese J Interv Imaging Ther"},{"key":"R6-20250905","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/15368378.2020.1741383","article-title":"Thermal ablation of biological tissues in disease treatment: A review of computational models and future directions","volume":"39","author":"Singh","year":"2020","journal-title":"Electromagn Biol Med"},{"key":"R7-20250905","doi-asserted-by":"crossref","first-page":"S705","DOI":"10.21037\/jtd.2016.09.42","article-title":"Percutaneous imaging-guided cryoablation for lung cancer","volume":"8","author":"Zhang","year":"2016","journal-title":"J Thorac Dis"},{"key":"R8-20250905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cryobiol.2013.11.001","article-title":"Mechanisms of cryoablation: Clinical consequences on malignant tumors","volume":"68","author":"Baust","year":"2014","journal-title":"Cryobiology"},{"key":"R9-20250905","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cryobiol.2013.10.005","article-title":"Alleviating the pain of unresectable hepatic tumors by percutaneous cryoablation: Experience in 73 patients","volume":"67","author":"Long","year":"2013","journal-title":"Cryobiology"},{"key":"R10-20250905","first-page":"23","article-title":"Expert consensus on clinical practice of multi-model ablation for treatment of liver malignant tumors","volume":"18","author":"Gao","year":"2021","journal-title":"Chinese J Interv Imaging Ther"},{"key":"R11-20250905","doi-asserted-by":"crossref","DOI":"10.1177\/15266028231215212","article-title":"Multicenter randomized controlled trial of APERTO-paclitaxel drug-eluting balloon angioplasty versus standard percutaneous transluminal angioplasty in dysfunctional hemodialysis grafts and native fistulae","author":"Maleux","year":"2023","journal-title":"J Endovasc Ther"},{"key":"R12-20250905","first-page":"221","article-title":"Haemorrhage Professional Committee of Chinese Research Hospital A, China Haemorrhage Center A. Expert consensus on emergency nursing for fatal haemorrhage (2019)","volume":"29","year":"2020","journal-title":"J Vasc Interv Radiol"},{"key":"R13-20250905","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/02656736.2018.1539253","article-title":"Engineering T cell response to cancer antigens by choice of focal therapeutic conditions","volume":"36","author":"Shao","year":"2019","journal-title":"Int J Hyperther"},{"key":"R14-20250905","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","article-title":"Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma-results of a prospective biomarker study","volume":"7","author":"Forschner","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R15-20250905","first-page":"14","article-title":"Mechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer","volume":"7","author":"Seto","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"R16-20250905","doi-asserted-by":"crossref","first-page":"930461","DOI":"10.3389\/fimmu.2022.930461","article-title":"Cryoablation reshapes the immune microenvironment in the distal tumor and enhances the anti-tumor immunity","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"R17-20250905","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/cancers16142560","article-title":"Advances in image-guided ablation therapies for solid tumors","volume":"16","author":"Campbell","year":"2024","journal-title":"Cancers"},{"key":"R18-20250905","doi-asserted-by":"crossref","first-page":"e1537581","DOI":"10.1080\/2162402X.2018.1537581","article-title":"Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients","volume":"8","author":"Lee","year":"2019","journal-title":"Oncoimmunology"},{"key":"R19-20250905","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat Med"},{"key":"R20-20250905","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/jcrt.jcrt_2405_23","article-title":"Immunohistochemical expression of PD-L1 and Ki67 in glioma and its correlation with treatment and overall survival","volume":"21","author":"Kumar","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R21-20250905","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.4103\/jcrt.jcrt_1887_24","article-title":"Effect of cryoablation on the spatial transcriptomic landscape of the immune microenvironment in non-small cell lung cancer","volume":"20","author":"Zhou","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R22-20250905","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment","volume":"20","author":"Davis","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"R23-20250905","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10585-023-10234-6","article-title":"Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver","volume":"41","author":"Huibers","year":"2024","journal-title":"Clin Exp Metastas"}],"updated-by":[{"DOI":"10.4103\/jcrt.jcrt_2543_25","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2146_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:32:31Z","timestamp":1787837551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2146_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2146_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2024-11-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}